23 Maret 2023: Terapi sél kanker preclinical sareng tahap awal anu dikembangkeun ku Shanghai biotéh Oricell nampi dana tambahan $ 45 juta, perusahaan ngumumkeun Salasa.
Saatos acara di ASCO taun ka tukang kalayan terapi CAR-T anu diarahkeun GPRC5D pikeun sababaraha myeloma, Oricell ngangkat Series B $ 120 juta dina bulan Juli. Investor anyar Qiming Venture Partners sareng C&D Emerging Industry Equity Investment dituturkeun ku investor anu tos aya RTW Investments sareng Qatar Investment Authority mingpin paningkatan panganyarna, anu mangrupikeun ékspansi babak éta.
Firma biotéh nyatakeun yén dana anu nembé kaala bakal dianggo utamina pikeun panalungtikan klinis di AS.
Oricell ngusahakeun sababaraha Terapi CAR-T and solid tumour antibody candidates. A group of patients with treatment-resistant sababaraha myeloma responded to Oricell’s GPRC5D-directed CAR-T with a 100% overall response rate and 60% stringent complete response in the Phase I trial that was presented at ASCO.
Anjeun panginten hoyong maca: Terapi T-Cell CAR di Cina
Khususna, Oricell nyorot sakelompok lima pasien anu parantos nampi BCMA Terapi CAR-T. Numutkeun perusahaan, hiji réspon parsial, dua "réspon parsial anu saé pisan," sareng dua réspon lengkep anu ketat sadayana nampi. Sareng kalayan tindak lanjut median ti 35 dugi ka 281 dinten, sadayana henteu aya kamajuan dina tanggal cutoff di ASCO.
Numutkeun kana Oricell, anu ayeuna aya dina tahap IND-aktipkeun, éta ngaharepkeun manjangkeun sidang pikeun terapi CAR-T anu diarahkeun ku GPRC5D ka AS.
Salaku tambahan, Oricell gaduh terapi sél CAR-T anu diarahkeun ku GPC3 anu disebut Ori-C101, anu nuju diajar dina carcinoma hépatocellular maju.
Terapi T-Cell mobil is among the breakthrough treatments for certain types of blood cancers. There are more than 750 ongoing percobaan klinis in CAR T-Cell therapy in China at present. Patients who wish to enroll can contact the KankerFax saluran pitulung pasien dina WhatsApp + 91 96 1588 1588 atanapi email ka info@cancerfax.com.
